PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'1DATA Consortium, Manhattan, USA. jaberi@k-state.edu.\', \'Kansas State University Olathe, Olathe, KS, 66061-1304, USA. jaberi@k-state.edu.\', \'Department of Mathematics, Kansas State University, Manhattan, USA. jaberi@k-state.edu.\', \'1DATA Consortium, Manhattan, USA.\', \'Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, USA.\', \'Kansas State University, Manhattan, USA.\', \'North Carolina State University, Raleigh, USA.\', \'Kansas State University Olathe, Olathe, KS, 66061-1304, USA.\', \'Department of Business Economics, University of Colombo, Colombo, Sri Lanka.\', \'Molecular Biology and Biochemistry, School of Biological and Chemical Sciences, University of Missouri-Kansas City, Kansas City, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41598-021-92734-7
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 34172790
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all